Explanation of Conflict of Interest Disclosure Parts:

Part One: All Financial Involvement with a pharmaceutical or biotechnology company, a company providing clinical assessment, scientific, or medical products or companies doing business with or proposing to do business with ACNP over past 2 years (Calendar Years 2011 - Present).

Part Two: Income Sources & Equity of \$10,000 per year or greater (Calendar Years 2011 - Present).

Part Three: Financial Involvement with a pharmaceutical or biotechnology company, a company providing clinical assessment, scientific, or medical products or companies doing business with or proposing to do business with ACNP which constitutes more than 5% of personal income (Calendar Years 2011 - Present)

Part Four: Grants from pharmaceutical or biotechnology company, a company providing clinical assessment, scientific, or medical products directly, or indirectly through a foundation, university, or any other organization (Calendar Years 2011- Present).

Part Five: My primary employer is a pharmaceutical/biotech/medical device company.

ACNP 2013 Council Disclosures

John Csernansky: Part 1: Eli Lilly & Company, Sanofi-Aventis; Part 4: Sunovion

Ron Duman: Part 1: Lundbeck, Eli Lilly & Company, Pfizer, Forest, Johnson & Johnson, Bristol-Myers Squibb

Alan Frazer: Part 1: Cyberonics, Eli Lilly & Company, Lundbeck, Takeda Industries; Part 4: Lundbeck

Suzanne Haber: Part 1: Medtronic, Inc., Pfizer

John Krystal: Part 1: AbbVie, Inc. (formerly Abbott), Amgen, AstraZeneca, Biological Psychiatry (Editor), Bristol-Myers Squibb, CHDI Foundation, Inc., Coalition for Translational Research in Alcohol & Substance Use Disorders BOD, Eli Lilly & Company, F. Hoffmann-LaRoche Ltd, Janssesn Research Foundation, Lohocla Research Corporation, Mnemosyne Pharmaceuticals, Inc., Naurex, Inc., Otsuka, Quintiles Consulting, Pfizer Pharmaceuticals, Teva Pharmaceuticals Industries, Ltd., Sage Therapeutics, Shire Pharmaceuticals, Sunovion, Takeda Industries, Tetragenex Pharmaceuticals, Part 2: Editor, Biological Psychiatry

Patents and Inventions

- 1. (pending) Seibyl JP, Krystal JH, Charney DS. Dopamine & noradrenergic reuptake inhibitors in treatment of schizophrenia. Patent #: 5,447,948. September 1995
- 2. (pending) Vladimir, Coric; Krystal, John Hm; Sanacora, Gerard Co-inventor Glutamate agents in the treatment of mental disorders No. 11/399,188. April5, 2006
- 3. (pending) Intranasal administration of ketamine to treat depression

David Kupfer: Part 1: American Psychiatric Association, Servier International (spouse), Guilford Press (spouse), Part 2: Consultant American Psychiatric Association, Servier International (spouse)

David Lewis: Part 1: Bristol-Myers Squibb, Concert; Part 4: Foundation, Bristol-Myers Squibb, Curridium, Ltd., Pfizer

Robert Malenka: Part 1: Circuit Therapeutics, Inc.; Part 2: Circuit Therapeutics, Inc.

Eric Nestler: Part 1: Berg Pharma, Johnson & Johnson, Merck, Neurolegix, PsychoGenics; Part 2: Berg Pharma, Merck, PsychoGenics; Part 3: Berg Pharma, Merck; Part 4: Johnson & Johnson

Council Members with No Disclosures

Karen Berman Linda Brady Peter Kalivas Ronnie Wilkins, Executive Director